Agomab Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying treatments for fibrotic and fibro-inflammatory conditions with high unmet need. Its pipeline includes small-molecule and antibody candidates that modulate growth-factor pathways implicated in organ scarring, including programs aimed at fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. The company has little commercial revenue and is focused on advancing candidates through clinical development rather than selling marketed drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | -11.7 | — |
| Q3 2025 | 0 | — | -18.3 | — |
| Q4 2025 | 0 | — | -17.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Citi Trends, Inc. (CTRN), Value Line, Inc. (VALU), Cerence Inc. (CRNC), Tectonic Therapeutic, Inc. (TECX), AVITA Medical, Inc. (RCEL), Falcon's Beyond Global, Inc. (FBYD)